H NMR (400 MHz
,
(S)-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine (2)
(R)-2-(9-(pyridin-2-yl)-6-oxaspiro [4.5] decan-9-yl)acetaldehyde 23 1 (80 mg, 0.31 mmol) and (S)-chroman-4-amine hydrochloride 25 3 (86 mg, 0.46 mmol) were dissolved in CH 2 Cl 2 /MeOH(10 mL, v/v=5:1) and stirred for 1 h before the addition of NaBH(OAc) 3 (263 mg, 1.24 mmol). The reaction was stopped after 12 h. After the reaction mixture was concentrated under rotavapor, the product 2 (30 mg, white solid) was isolated from Prep-TLC. Yield is 25%. and stirred for 1 h before the addition of NaBH(OAc) 3 (144 mg, 0.68 mmol). The reaction was stopped after 11 h. After the reaction mixture was concentrated under rotavapor, the product 4 (15 mg, yellow solid) was isolated from Prep-TLC. Yield is 28.3%. 
HRMS m/z (ESI)
:
(S)-N-(2-((R
)
HRMS m/z (ESI)
:S5 (S)-4-((2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2H)-S6 i:(1R,4S)-4-((2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,
(S)-4-((2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2 H)-one (9)
i: (S)-1,2,3,4-tetrahydronaphthalen-1-amine 19 5 (3.0 g, 20.4 mmol), di-tert-butyl dicarbonate (4.9 g, 44.5 mmol) and triethyl amine (5.7 mL, 40.8 mmol) were dissolved in CH 2 Cl 2 (100 mL). The reaction was stopped after 12 h and washed by water (100 mL) and NaHCO 3 aqueous solution (100 mL). The organic phase was dried over Na 2 SO 4 and concentrated to deliver product 20 (5.6 g, yellow oil) without further purification. ii: tert-butyl ((1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl)carbamate 36 (60 mg, 0.228 mmol) was dissolved in CH 2 Cl 2 (5 mL) and TFA (0.5 mL) was added. After 2 h, the reaction mixture was concentrated to deliver crude product 37 (66 mg, yellow oil) without further purification. 
MS m/z (ESI)
(E)-2-((S)-4-((2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthal en-1(2H)-ylidene)acetonitrile (10)

MS m/z (ESI)
S13 (S)-6-fluoro-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine (3)
S14
The synthesis of 3 followed the similar procedure of 2. 
HRMS m/z (ESI)
(S)-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-4,5,6,7-tetrahydrobenzo[b]thiophe n-4-amine (13)
The synthesis of 13 followed the similar procedure of 4. 
HRMS m/z (ESI)
(S)-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-3',4'-dihydro-2'H-spiro[[1,3]dioxol ane-2,1'-naphthalen]-4'-amine (17)
The synthesis of 17 followed the similar procedure of 18. 
HRMS m/z (ESI)
S17
Methods for in vitro, in vivo, and pharmacokinetic assays
In vitro CYP inhibition assay
The inhibitory IC50 values of SHR9352 for five major P450 enzymes was determined in human liver microsomes (BD Gentest) by similar conditions as described in literatures. 8, 9 In Vitro Cellular Assays.
Cell 
cAMP Accumulation Assay
Receptor G protein mediated responses were determined by measuring changes in cAMP using the Luciferase Reporter cell lines and ONE-Glo™ Luciferase Assay System(Promega, USA). MOR, KOR, and DOR all couple to Gai, so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1µM forskolin (Sigma catalog #F6886). cAMP accumulation assay was run using HEK293 stably transfected to oipiod receptors and luciferase reporter genes. After 5 hours drug treatment, ONE-Glo™ Luciferase Assay Reagent was added to the cells for cell lysis and reaction signal reading by Luminometer (Victor 3, PerkinElmer, USA).
Detailed Procedure: The initial concentration was 1000 nM, 3-fold serial titration and 10 points were tested. On day 1, about 1 X 10^ 5 cells per well were seeded; On Day 2, compounds were titrated with DMSO and then transferred into each cell well on assay plate. Total assay volume was 100 µL per well.
After compounds were added, the assay plate were incubated for 5 h a at 37 °C and then 100 µL a The Luciferase Reporter cell line system contained an cAMP response element (CRE) that drove the transcription of the luciferase reporter gene luc2P. It was an indirect cAMP detection system which delivered a delayed signal. Only after reporter gene was transfcripted, the signal could be detected. So more time was required for incubation. We have optimized the assay incubation time and it was found 5 h was a proper incubation time.
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detection reagent were added into each well; Finally, after incubation for 5 min at room temperature, the assay plate were read by the microplate reader.
β-Arrestin-2 Recruitment Assay
The PathHunter enzyme complementation assay (DiscoveRx Corporation, Fremont, California) was performed according to the manufacturer's discription. Briefly, when β-arrestin-2 translocates to active receptor, the complementary β-galactosidase fragments fused to receptor and β-arrestin interact to form a functional enzyme, which is detected by chemiluminescence. β-arrestin-2 recruitment assay was run using CHO-K1 cells stably transfected to OPRM1and overexpress β-arrestin-2 fused to a β-galactosidase fragment.
Detailed Procedure: compound initial concentration was 10000 nM, 3-fold titration and 10 points were tested. On day 1, about 1 X 10^ 4 cells per well were seeded. On day 2, compounds were titrated with DMSO and then transferred into each cell well on assay plate. Total assay volume was 100 µL per well.
After compounds were added, the assay plate were incubated for 90 min at 37 °C and then add 50 µL detection reagent were added into each well, Finally, after incubation for 60 min at room temperature, the assay plate were read by the microplate reader.
In vivo PK studies
Animals utilized for preclinical studies include nude mice, rats and dogs. All animals were treated in 
In vivo Rat Incisional Pain Study
In vivo efficacy experiments were conducted in male wistar rats (200-250 g). Animals were housed in standard conditions with a 12-hour light/dark cycle for 72 hour prior to surgery. 10, 11 The measurement of tactile sensitivity for the injured hindpaw was obtained using von Frey filaments (UGO BASILE， #38450). Twenty-four hours after surgery, every 8 animals were randomly assigned to Model, TRV130, or SHR9352 treatment groups. Both compounds were administered i.v. as a bolus in the rat tail in a volume of 1 ml/kg. Allodynia was measured 30 minutes after drug administration.
The percentage of pain reduction effect was calculated as follows: [(treatment group -model group)/ model group] *100.
In vivo Mouse Gastrointestinal Function Study-Small Intestinal Transit test
In vivo gastrointestinal transit of the small intestine was measured using the charcoal meal test. 
